Abstract
Alzheimer’s disease (AD) remains a major health problem, and accounts for 50 to 60% of all cases of dementia. The two histopathological hallmarks of AD are senile plaques, composed of the β-amyloid peptide (Aβ), and intraneuronal neurofibrillary tangles composed of abnormally hyperphosphorylated tau protein. Only a small proportion of AD is due to mutations in the genome of patients, the large majority of cases being of late onset and sporadic in origin. The relative contribution of genetics and environment to the sporadic cases is unclear, but they are accepted to be of multifactorial origin. This means that genetic and environmental factors can interact together to induce or accelerate the disease. Among environmental factors, studies suggest that hypothermia may contribute to the development and exacerbation AD. Here, we review the preclinical data involving hypothermia with tau and Aβ, as well as clinical evidence implicating hypothermia in the development of AD. Keywords: Alzheimer’s dementia, tau, beta
Keywords: Alzheimer’s dementia, tau, beta-amyloid, phosphorylation, hypothermia, PP2A, phosphatases.
Current Alzheimer Research
Title:Hypothermia and Alzheimer's Disease Neuropathogenic Pathways
Volume: 7 Issue: 8
Author(s): R. A. Whittington, M.-A. Papon, F. Chouinard-Decorte and E. Planel
Affiliation:
Keywords: Alzheimer’s dementia, tau, beta-amyloid, phosphorylation, hypothermia, PP2A, phosphatases.
Abstract: Alzheimer’s disease (AD) remains a major health problem, and accounts for 50 to 60% of all cases of dementia. The two histopathological hallmarks of AD are senile plaques, composed of the β-amyloid peptide (Aβ), and intraneuronal neurofibrillary tangles composed of abnormally hyperphosphorylated tau protein. Only a small proportion of AD is due to mutations in the genome of patients, the large majority of cases being of late onset and sporadic in origin. The relative contribution of genetics and environment to the sporadic cases is unclear, but they are accepted to be of multifactorial origin. This means that genetic and environmental factors can interact together to induce or accelerate the disease. Among environmental factors, studies suggest that hypothermia may contribute to the development and exacerbation AD. Here, we review the preclinical data involving hypothermia with tau and Aβ, as well as clinical evidence implicating hypothermia in the development of AD. Keywords: Alzheimer’s dementia, tau, beta
Export Options
About this article
Cite this article as:
A. Whittington R., Papon M.-A., Chouinard-Decorte F. and Planel E., Hypothermia and Alzheimer's Disease Neuropathogenic Pathways, Current Alzheimer Research 2010; 7 (8) . https://dx.doi.org/10.2174/156720510793611646
DOI https://dx.doi.org/10.2174/156720510793611646 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemistry and Biology of Thyrotropin-Releasing Hormone (TRH) and its Analogs
Current Medicinal Chemistry The Cholinergic Potential, the Vagus Nerve and Challenges in Treatment of Traumatic Brain Injury
Current Pharmaceutical Design Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies
CNS & Neurological Disorders - Drug Targets Immunotherapy for Targeting Tau Pathology in Alzheimer’s Disease and Tauopathies
Current Alzheimer Research Expanding the Therapeutic Potential of Statins by Means of Nanotechnology Enabled Drug Delivery Systems
Current Topics in Medicinal Chemistry Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Neuroimaging Outcomes in Studies of Cognitive Training in Mild Cognitive Impairment and Early Alzheimer’s Disease: A Systematic Review
Current Alzheimer Research Ca2+ Signalling in Damaged Endothelium and Arterial Remodelling: Do Connexin Hemichannels Provide a Suitable Target to Prevent In-stent Restenosis?
Current Drug Therapy A Perspective on Clinical Islet Transplantation: Past, Present and Developments for Future
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Protective Effects of Polydatin Against Dementia-Related Disorders
Current Neuropharmacology Responders to ChEI Treatment of Alzheimers Disease Show Restitution of Normal Regional Cortical Activation
Current Alzheimer Research PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets AD Vaccines: Conclusions and Future Directions
CNS & Neurological Disorders - Drug Targets Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Genetic Bases of Progressive Supranuclear Palsy: The MAPT Tau Disease
Current Medicinal Chemistry Noninvasive Monitoring of Intracranial Pressure
Recent Patents on Biomedical Engineering (Discontinued) Neurological Aspects of Medical Use of Cannabidiol
CNS & Neurological Disorders - Drug Targets Dimerization of C-terminal Truncations of α-synuclein and its Effect on the Aggregation Propensity: A Potential of Mean Force Study
Current Chemical Biology Inherent Aggregation Propensity of Flanking Residues Attached to Polyglutamines: Implication to Aggregation Inhibition
Protein & Peptide Letters Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry